Cardiology · 1954
Warfarin introduced for clinical anticoagulation
The problem that warfarin eventually addressed had been building since heparin came into clinical use in the 1930s. Heparin required intravenous administration and continuous monitoring, making it impractical for outpatient anticoagulation of conditions like atrial fibrillation and deep vein thrombosis. Physicians needed something a patient could take by mouth at home. The compound that filled that need had an unusual origin: a hemorrhagic disease in cattle eating spoiled sweet clover silage, first observed on farms in North Dakota and Alberta in the early 1920s.
Karl Paul Link, a biochemist at the University of Wisconsin, identified the toxic compound in 1939 as bishydroxycoumarin and spent the following years developing more potent coumarin derivatives. The name warfarin was an acronym for the Wisconsin Alumni Research Foundation, which held the patent, plus the suffix -arin from coumarin. The compound was first registered as a rodenticide in 1948. Its mechanism, inhibition of vitamin K-dependent clotting factor synthesis in the liver, made it lethal at high doses but controllable at low ones.
Warfarin entered clinical use in 1954, initially for venous thromboembolism and then for atrial fibrillation stroke prevention. Its narrow therapeutic index made it challenging: the difference between an INR that protected against clot and one that caused bleeding was small. Drug interactions were extensive, spanning antibiotics, anti-inflammatory agents, and antifungals. Dietary vitamin K from leafy vegetables shifted the dose-response curve. Management required regular INR testing and dose adjustment, typically by a physician or anticoagulation clinic.
Despite these limitations, warfarin dominated anticoagulation for roughly five decades. Clinical trial evidence supported its use in mechanical heart valves, non-valvular atrial fibrillation, and venous thromboembolism. No competitor with comparable evidence and oral availability existed until the direct oral anticoagulants appeared. Dabigatran, a direct thrombin inhibitor, received regulatory approval in the United States in 2010; the factor Xa inhibitors rivaroxaban and apixaban followed shortly after.
The newer agents offered fixed dosing, fewer drug interactions, and no requirement for routine monitoring. They displaced warfarin rapidly in atrial fibrillation and venous thromboembolism. Warfarin retains a specific remaining indication: patients with mechanical prosthetic heart valves, where trials of the direct oral anticoagulants have shown inferior outcomes, likely because mechanical valves generate thrombus through a different mechanism. In that narrow population, the compound Link isolated from spoiled clover is still the standard of care.
Key People
- Karl Paul Link — University of Wisconsin biochemist who isolated and developed coumarin anticoagulants.
- Lee Roderick — Veterinary pathologist who first characterized the hemorrhagic cattle disease.
J Saudi Heart Assoc, 2016 (history review)
Related landmarks
- 1953 · First Successful Open-Heart Surgery Using the Heart-Lung Machine (Cardiology)
- 1958 · First implantation of a permanent cardiac pacemaker (Senning and Elmqvist) (Cardiology)
- 1961 · Factors of Risk in the Development of Coronary Heart Disease (Framingham Heart Study) (Cardiology)
- 1980 · Implantable cardioverter-defibrillator first human implantation (Mirowski) (Cardiology)